Scintec Diagnostics Gmbh

Therapharm Gmbh

Ivan Benes

Silke Thomsen-Bosslet

Klaus Bosslet

Kim Orchard

Ladislav Droz

The present invention relates to the use of radioimmunoconjugates for the treatment of haematological malignancies, particularly multiple myeloma.

Immunoconjugate for human CD66 for the treatment of multiple myeloma and other haematological malignancies

The invention relates to (glyco-) proteins, in particular monoclonal antibodies, which have an immunoreactivity of &#x3e;81%, preferably &#x3e;90%. The inventive monoclonal antibodies are produced using a fluidized bed reactor in conjunction with a conventional protein-chemical purification method or preferably with a purification method involving less column chromatography. The monoclonal antibodies thus produced are suitable, in gamma-irradiated form, e.g. Tc-99m labeled, for the in vivo diagnosis of inflammatory diseases and bone marrow metastases. In alpha- or beta-irradiated form, e.g. astatine or Re-188 or Y-90 labeled form, the inventive monoclonal antibodies can be used, for example, in the treatment of leukemia.

Proteins with high immunoreactivity and method for their production

The invention relates to (glyco-) proteins, in particular monoclonal antibodies, which have an immunoreactivity of &#x3e;81%, preferably &#x3e;90%. The inventive monoclonal antibodies are produced using a fluidized bed reactor in conjunction with a conventional protein-chemical purification method or preferably with a purification method involving less column chromatography. The monoclonal antibodies thus produced are suitable, in gamma-irradiated form, e.g. Tc-99m labelled, for the in vivo diagnosis of inflammatory diseases and bone marrow metastases. In alpha- or beta-irradiated form, e.g. astatine or Re-188 or Y-90 labelled form, the inventive monoclonal antibodies can be used, for example, in the treatment of leukemia.

Growing community of inventors

Forch, Switzerland

Ivan Benes